Catalent

Catalent logo

Catalent, Inc. is a global provider of delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. Founded in 2007 as a spin-off from Cardinal Health, Catalent has grown to become a leader in the development of innovative delivery technologies that improve the bioavailability of drugs, enhance clinical efficacy, and increase patient adherence to medication regimens.

History

Catalent was established in April 2007 when the private equity firm Blackstone Group acquired the Pharmaceutical Technologies and Services segment of Cardinal Health for $3.3 billion. The company was named Catalent, a blend of "catalyst" and "talent," to reflect its mission of combining innovative technologies and talented experts to advance pharmaceutical development and manufacturing. Since its inception, Catalent has expanded its global footprint and capabilities through strategic acquisitions and investments in research and development.

Services

Catalent offers a wide range of services across the drug development and supply chain, from early-stage development to commercial supply. These services include:

• Drug Development: Catalent provides formulation development, analytical testing, and regulatory support to optimize the delivery and performance of drugs.
• Drug Delivery Technologies: The company specializes in advanced delivery technologies such as softgel capsules, modified release formulations, and biologic drug delivery systems to enhance the bioavailability and effectiveness of medications.
• Manufacturing: Catalent offers manufacturing services for a variety of dosage forms, including oral, injectable, inhalable, and topical products. The company operates state-of-the-art facilities that comply with global regulatory standards.
• Clinical Supply Services: Catalent supports clinical trials worldwide with services such as supply chain management, packaging, and global distribution.

Innovations and Technologies

Catalent is known for its innovative approach to drug delivery and formulation. Some of its notable technologies include:

• OptiMelt™ Hot Melt Extrusion: This technology enhances the solubility and bioavailability of poorly water-soluble drugs.
• Zydis® Orally Disintegrating Tablet: Zydis technology allows tablets to dissolve rapidly in the mouth without the need for water, improving patient compliance.
• GPEx® Technology: A proprietary technology for the development and manufacturing of biologic drugs, including monoclonal antibodies and recombinant proteins.

Acquisitions

Over the years, Catalent has strategically acquired several companies to broaden its service offerings and technological capabilities. These acquisitions have enabled Catalent to enter new markets and expand its expertise in drug delivery and manufacturing.

Corporate Responsibility

Catalent is committed to corporate responsibility, with a focus on environmental sustainability, ethical business practices, and community engagement. The company aims to reduce its environmental impact through energy-efficient operations and sustainable packaging solutions.

Conclusion

Catalent, Inc. plays a crucial role in the pharmaceutical and biotechnology industries by providing innovative solutions for drug development, delivery, and manufacturing. With its extensive range of services, global presence, and commitment to quality and sustainability, Catalent continues to be a key partner for companies looking to bring new therapies to market.